OXLUMO Trademark
OXLUMO is a USPTO trademark filed by Alnylam Pharmaceuticals, Inc.. Status: Registered.
Prosecution Summary
**Trademark Summary** **OXLUMO** is a standard character mark covering pharmaceutical preparations for the treatment of primary hyperoxaluria in International Class 005. It is **registered** on the Principal Register (Reg. No. 6295911, issued March 16, 2021) and owned by **Alnylam Pharmaceuticals, Inc.**, a Delaware corporation based in Cambridge, Massachusetts. A security interest has been recorded in favor of **Bank of America, N.A.** as of October 1, 2025, with Alnylam remaining the registrant. **Recent Activity** Filed March 22, 2019, the mark was published for opposition July 16, 2019, issued a Notice of Allowance September 10, 2019, and progressed through statement of use extensions before registration on March 16, 2021. A courtesy reminder for Section 8 maintenance was issued f
Trademark Facts
| Mark | OXLUMO |
|---|---|
| Serial Number | 88352142 |
| Registration Number | 6295911 |
| Status | Registered |
| Filing Date | 2019-03-22 |
| Registration Date | 2021-03-16 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Alnylam Pharmaceuticals, Inc. |
| Attorney of Record | Timothy H. Hiebert |
| Prosecution Events | 27 |
| Latest Event | REM1 on 2026-03-16 |
Goods & Services
Pharmaceutical preparations for the treatment of primary hyperoxaluria